Regulus Therapeutics Inc. (NASDAQ:RGLS) Given Average Recommendation of “Hold” by Analysts
Regulus Therapeutics Inc. (NASDAQ:RGLS – Get Free Report) has received an average rating of “Hold” from the seven research firms that are currently covering the firm, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12-month target price […]
Regulus Therapeutics Inc. (NASDAQ:RGLS – Get Free Report) has received an average rating of “Hold” from the seven research firms that are currently covering the firm, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12-month target price […]
